NCT03014245

Brief Summary

Melatonin is well known for its role in the sleep-wake cycle but it is less well known as an effective antioxidant. It has been reported to be synthesised in the placenta and may have both receptor mediated and non-receptor mediated protective functions during pregnancy. Severe pre-eclampsia has been reported to be associated with low levels of melatonin in the placenta although it is not known if the placental melatonin contributes to circulating levels. There is little reported on the circulating levels of melatonin or oxidative stress at different stages of normal pregnancy. More information on the role of melatonin and metabolism of melatonin in pregnancy as well as any significant association with adverse pregnancy outcomes would inform planning of larger research studies to investigate the potential role for melatonin as a biomarker for obstetric disease and potentially as a therapeutic agent in future. This observational pilot study aims to measure serum melatonin levels and 6-hydroxymelatonin sulphate (the major metabolite of melatonin) during each trimester of pregnancy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2016

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 12, 2016

Completed
28 days until next milestone

First Posted

Study publicly available on registry

January 9, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 18, 2017

Completed
Last Updated

May 8, 2026

Status Verified

January 1, 2017

Enrollment Period

5 months

First QC Date

December 12, 2016

Last Update Submit

May 4, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in melatonin and 6-hydroxymelatonin levels during pregnancy

    Do serum melatonin and 6-hydroxymelatonin sulphate levels differ in each trimester of pregnancy? Levels during each trimester will be compared.

    Values up to 40 weeks

Secondary Outcomes (6)

  • Change in lipid peroxide levels during pregnancy

    Values up to 40 weeks

  • Relationship between melatonin and 6-hydroxymelatonin levels and duration of pregnancy.

    Up to 40 weeks

  • Relationship between melatonin and 6-hydroxymelatonin levels with different types of delivery.

    Up to 40 weeks

  • Relationship between melatonin and 6-hydroxymelatonin levels and pre-eclampsia

    Up to 40 weeks

  • Relationship between melatonin and 6-hydroxymelatonin levels and gestational diabetes

    Up to 40 weeks

  • +1 more secondary outcomes

Study Arms (2)

Pregnant

Normal pregnant women (first baby) singleton

Control

Non pregnant healthy women

Eligibility Criteria

Age16 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Healthy women pregnant with first baby (singleton) presenting for first trimester scan and healthy non-pregnant women of child bearing age.

You may qualify if:

  • Pregnant subjects
  • Primigravid women (in their first pregnancy)
  • Singleton pregnancy
  • Aged 16-45
  • Taking no regular medication other than pregnancy related vitamins or supplements
  • First trimester (FVS) ultrasound scan reported as normal
  • Non pregnant subjects
  • Non pregnant women
  • Aged 16-45
  • No chronic health issues and not taking any medication

You may not qualify if:

  • Pregnant subjects
  • Pregnancy non-viable on scan
  • Twins or higher multiple pregnancies
  • Outside age range
  • Diabetes or pre-existing hypertension, chronic kidney disease or known autoimmune disorder
  • Non pregnant subjects
  • Male
  • Outside age range
  • Chronic health complaint/taking medication
  • Recent blood donation over 1 unit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aberdeen Maternity Hospital (NHS Grampian)

Aberdeen, Aberdeenshire, AB25 2ZB, United Kingdom

Location

Related Links

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood

MeSH Terms

Conditions

Hypertension, Pregnancy-Induced

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesHypertensionVascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 12, 2016

First Posted

January 9, 2017

Study Start

November 1, 2016

Primary Completion

April 1, 2017

Study Completion

May 18, 2017

Last Updated

May 8, 2026

Record last verified: 2017-01

Data Sharing

IPD Sharing
Will not share

Locations